That is a deliberately narrow claim: the number is what the protocol says, the math shows exactly how it converts to a syringe draw, and everything about whether the compound does anything in a human is left to the honest evidence section rather than smuggled into the dose
GHK-Cu 100mg is not the same type of peptide as BPC-157, but it is an adjacent research compound because it is studied in extracellular matrix, collagen, copper peptide and wound biology models
In the future, large-scale real-world studies are needed to confirm our findings for patients treated with oral or injectable semaglutide and potentially compare treatment effects of each formulation within the same patient population
Neither compound has published the kind of long-term hard-outcome data (cardiovascular events, mortality) that ultimately defines a metabolic drugs value, because both are too early in development for that
Another issue is the difficulty in determining the specific moment at which cancer cells undergo senescence [5]